Logo
TEOFIL Sub Q 1.1 ml

TEOFIL Sub Q 1.1 ml

TEOFIL (Teofil)

Medical device — hyaluronic acid dermal filler
  • CE certified (manufacturer brochure explicitly states CE certification for the TEOFIL family; brochure indicates compliance with medical device regulations for CE marking).
  • Manufacturer states ISO 13485 quality management compliance.
  • Manufacturer claims HCCL™ manufacturing minimizes residual BDDE and delivers a stabilized 3D matrix (manufacturer technical claims in brochure).
  • Clinical trial summary included in manufacturer brochure indicating comparative testing vs. reference device (brochure pages summarise clinical/efficacy assessments).
Monophasic HA dermal filler for deep dermis / subcutaneous volumising (contouring)

Description

TEOFIL Sub-Q is a CE-certified, monophasic cross-linked hyaluronic acid (HA) filler manufactured using HCCL™ (Highly Completed Cross-Linking) technology. Formulated as a high-viscosity, viscoelastic gel for deep dermal and subcutaneous placement, Sub-Q is designed to restore lost facial volume and enhance contours in areas such as the chin, jawline and cheeks. The product is supplied in a prefilled syringe (1.1 ml) and includes lidocaine (0.3%) to increase patient comfort during injection. Manufacturer product literature states CE classification as a Class III medical device and lists composition, recommended injection depth and pack contents.

Bnefits

  • High-viscosity monophasic gel providing structural support for facial contouring (chin, jawline, cheeks)
  • HCCL™ advanced cross-linking manufacturing process claimed to improve stability and minimize pendant BDDE
  • Contains lidocaine (0.3%) for reduced injection discomfort
  • 20 mg HA per ml concentration for volumising and hydration
  • Supplied as a ready-to-use prefilled syringe with recommended needle gauges for clinical use
  • CE marked (manufacturer-stated) and produced under ISO 13485 quality processes per manufacturer literature

Indications

  • Enhancement of facial contours and restoration of lost volume (chin, jawline, cheeks)
  • Volumising applications requiring durable structural support via medium-to-deep/subcutaneous placement
  • General facial contouring where a high-viscosity HA filler is clinically indicated

Composition

  • Cross-linked hyaluronic acid (HA) — 20 mg/ml (manufacturer product summary)
  • Lidocaine — 0.3% (manufacturer product summary)
  • Cross-linking performed via HCCL™ manufacturing process (manufacturer claim; exact cross-linker residuals not published)

Formulation

  • Monophasic hyaluronic acid gel with enhanced viscoelasticity for deep/subcutaneous injection
  • Prefilled sterile syringe (1.1 ml) intended for single use
  • Pack includes recommended needle gauges (manufacturer product summary lists 1 x 25G needle and 1 x 27G needle for Sub-Q)

Packaging

  • Typically supplied as 1 x 1.1 ml prefilled syringe in sterile single-use packaging (manufacturer brochure / distributor listings)
  • Individual syringe packaged with needles and product leaflet; carton and artwork may vary by region and distributor

Usage

Not publicly listed

Contraindications

  • Not publicly listed

Adverse Effects

  • Not publicly listed

Storage Conditions

  • Manufacturer/distributor materials reference standard storage in original packaging, protected from extreme temperatures and direct sunlight; consult product labelling/IFU for exact temperature range.
  • Keep sterile until use and store in a clean, dry place as indicated on carton/leaflet.

Duration

Not publicly listed (manufacturer/distributor materials describe 'long-lasting' results; no fixed duration guarantee is published \u2014 clinical duration depends on individual factors and is variable)

Onset

Not publicly listed (immediate visible volumising/smoothing effect expected upon injection; brochure does not quantify onset time)

Browse more Medical device \u2014 hyaluronic acid dermal filler

Top Treatments

Top Cities in the UK